The global outpatient oncology infusion market revenue was US$ 2.4 billion in 2023. The global market is estimated to reach US$ 5.94 billion by 2032, growing at a compound annual growth rate (CAGR) of 10.6% during the forecast period.
Outpatient oncology infusion refers to the process of administering chemotherapy, cancer immunotherapy, or other cancer treatments in a specialized clinic or infusion center rather than in a hospital setting. This method allows patients to receive their medications intravenously while spending less time in medical facilities and more time at home, which can significantly enhance their quality of life. This approach improves patient comfort and contributes to better disease management. By providing continuity of care, outpatient infusion centers help patients manage their symptoms more effectively.
Factors Influencing the Global Outpatient Oncology Infusion Market Growth
The outpatient oncology infusion market is primarily fueled by the growing prevalence of cancer and the subsequent increase in demand for oncology treatments. The global incidence of cancer continues to escalate, largely due to factors such as aging populations, lifestyle choices, and environmental influences. As the number of individuals diagnosed with cancer rises, the need for effective oncology treatments?including infusion therapies provided in outpatient settings?becomes increasingly critical. This trend underscores the essential role of outpatient infusion in meeting the healthcare needs of cancer patients.
Recent technological advancements in cancer therapies, including immunotherapies, targeted therapies, and personalized medicines, are increasingly characterized by manageable side effects, making them well-suited for outpatient administration. Additionally, the emergence of portable and wearable infusion pumps facilitates continuous or periodic infusion of therapies in outpatient settings. This development enhances patient convenience and comfort, allowing more flexible treatment options. As a result, these factors are creating lucrative opportunities for growth in the global outpatient oncology infusion market.
The reimbursement process for outpatient oncology infusion therapy encompasses several critical steps, including pre-authorization, thorough documentation, and adherence to various payment standards. Consequently, navigating this complex reimbursement landscape poses a significant barrier to the growth and expansion of the outpatient oncology infusion market. These challenges can hinder access to necessary treatments for patients and create obstacles for healthcare providers aiming to deliver effective oncology care.
Regional Analysis
North America is projected to lead the global outpatient oncology infusion market in revenue share by the end of 2032. This anticipated growth is largely attributed to the expanding outpatient care industry and the presence of advanced healthcare infrastructure in the region. As a result, outpatient facilities and services are proliferating, enabling medical centers to reduce the number of patient visits and lower healthcare costs for cancer patients.
In the United States, the outpatient oncology infusion market is undergoing continuous transformation due to increasing healthcare spending. This rise in funding allows researchers to focus on innovation, leading to more precise and effective treatment options for patients. According to a 2024 report from the American Medical Association, healthcare spending in the U.S. rose by 4.1% in 2022.
In Canada, the landscape is also promising, with a growing number of IV infusion therapies currently approved and several more under consideration for future approval. This trend is expected to enhance cancer treatment options and contribute to the market's expansion.
List of Key Companies
- B. Braun Melsungen AG
- Baxter
- Becton, Dickinson, and Company
- Fresenius Kabi
- ICU Medical, Inc
- IRadimed Corporation
- Medtronic PLC
- Micrel Medical Devices SA
- Moog, Inc.
- Nipro Corporation
- Roche Diagnostics
- Smiths Medical
- Teleflex, Inc.
- Terumo Corporation
- Other Prominent Players
Market Segmentation Outline
The global outpatient oncology infusion market segmentation focuses on Product, Application, Therapy, Mode, and Region.
By Product
- Infusion pumps
- Intravenous sets
- IV cannulas
- Needleless connectors
By Application
- Lung cancer
- Liver cancer
- Breast cancer
- Prostate cancer
- Other cancers
By Therapy
- Chemotherapy
- Targeted therapy
- Immunotherapy
- Hormonal therapy
By Mode
- Intramuscular (IM)
- Intravenous (IV)
- Subcutaneous
- Other modes
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Western Europe
- The UK
- Germany
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Poland
- Russia
- Rest of Eastern Europe
- Asia Pacific
- China
- India
- South Korea
- Japan
- Australia & New Zealand
- ASEAN
- Malaysia
- Myanmar
- Philippines
- Singapore
- Thailand
- Vietnam
- Indonesia
- Cambodia
- Rest of ASEAN
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- UAE
- Saudi Arabia
- South Africa
- Rest of MEA
- South America
- Argentina
- Brazil
- Rest of South America